Skip to main content
OpenTrials
Completed

NCT Number: NCT00504712

Testosterone for Peripheral Vascular Disease

There is increasing evidence of the linkage of type 2 diabetes with low testosterone levels in men.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

Barnsley Hospital NHS Foundation Trust

Barnsley, South Yorkshire, S75 2EP, United Kingdom

About this study

Testosterone treatment has shown beneficial effects on blood sugar control and obesity in pilot studies in men with type 2 diabetes. Beneficial effects have also been seen on angina- a disease related to atherosclerosis (narrowing of the arterial blood vessels). Peripheral vascular disease is also caused by atherosclerosis. We hypothesise that testosterone will have beneficial effects on peripheral vascualr disease in men with low serum testosterone and type 2 diabetes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetes mellitus.
  • Serum testosterone 12 nmol/L or less on two consecutive samples taken on different days and symptoms compatible with hypogonadism.
  • Peripheral vascular disease as defined by
  • previous diagnosis by a specialist vascular surgeon OR
  • ABPI less than 0.92 and ischaemic leg pain (claudication or rest pain) or distal complications (non-healing arterial foot ulcer or gangrene).
  • Agreement to maintain antihypertensive and antilipid treatments at prior doses during 3 month duration of study.
  • Ability to give written informed consent after verbal and written explanation in the English language.
  • Ability to comply with all study requirements.

Exclusion criteria

  • Current or previous breast cancer.
  • Current or previous prostate cancer.
  • Raised prostate specific antigen (PSA) or abnormal per rectal examination unless prostate cancer excluded after specialist urology opinion.
  • Severe symptoms of benign prostatic hypertrophy ('prostatism')
  • Treatment with testosterone in the 3 months prior to the trial.
  • Investigational drug treatment in the 3 months prior to the trial.

Treatment and study plan

Testosterone

Drug

Sustanon- 200mg- Intramuscular testosterone every 2 weeks

Saline

Drug

Saline injection every two weeks

Primary outcomes

  1. Change in Arterial Stiffness

    Time frame: Baseline, 12 weeks, and 26 weeks

    The primary outcome was the effect of 12 weeks testosterone replacement on arterial stiffness measured by ultrasound derived stiffness parameter β of the femoral artery. A reduction in ultrasound derived stiffness parameter β is clinically beneficial to patients and the study was looking for a reduction in this value. Stiffness index β was calculated from the diastolic carotid artery diameter (Dd), systolic carotid artery diameter (Ds), diastolic blood pressure (BPd) and systolic blood pressure (BPs) using the formula; Stiffness index β = (ln(Ps/Pd)) x Dd/(Ds-Dd). A full theoretical range of possible index scores does not exist.

Secondary outcomes

  1. Change in IMT

    Time frame: Baseline, 12 weeks, and 26 weeks

    Progression of Carotid intima-media thickness measured in mm

Sponsors and collaborators

Lead sponsor

Barnsley Hospital

Other

Registry information

Official study title

A Randomised, Double Blind, Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Jul 20, 2007
Registry last updated
Jun 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.